Olumiant
Lilly & Incyte’s Olumiant hits main goal in atopic dermatitis
January 28, 2020Manufacturing and Production, Research and Development Eli Lilly, Olumiant, pharma
Eli Lilly and Incyte have lifted the curtain on new Phase 3 data showing that their oral JAK inhibitor, showing …
New ICER report reveals most cost-effective rheumatoid arthritis therapies
November 27, 2019Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma
The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …
Lilly’s Olumiant impresses in twin Phase 3 atopic dermatitis trials
February 5, 2019Manufacturing and Production, Research and Development Eli Lilly, Olumiant, atopic dermatitis, pharma
Eli Lilly has unveiled new Phase 3 data from two studies into the oral Janus kinase (JAK) inhibitor Olumiant (baricitinib). …
FDA greenlights Lilly’s Olumiant in rheumatoid arthritis, with major caveats
June 5, 2018Manufacturing and Production, Sales and Marketing Eli Lilly, FDA, Olumiant, pharma
Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely …
Eli Lilly arthritis drug outperforms Humira and receives NICE backing
June 30, 2017Medical Communications, Research and Development, Sales and Marketing Eli Lilly, NICE, Olumiant, rheumatoid arthritis
Eli Lilly’s rheumatoid arthritis (RA) drug Olumiant (baricitinib) has been deemed cost-effective by NICE and has been recommended to be …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
